There are pressures on Big Pharma and biotech emerging companies alike to engage in more creative deal making to ensure positive outcomes for both parties, Ted Agres writes in Drug Discovery and Development. While the number of deals has remained relatively flat in 2011, the dollar amount of individual deals has increased overall. Oncology remains the most sought after category, followed by CNS, anti-infectives, metabolic diseases, dermatology and cardiovascular.
Partnering activity at BIO events is on the rise, as well. At the 2012 BIO Business Forum during the BIO International Convention, BIO hosted an unprecedented number of partnering meetings – 21,183. The upcoming BIO CEO & Investor Conference is the largest investor conference focused on publicly-traded biotech companies and is expected to draw a significant amount of interest from attendees in partnering.
Check out the December 1 issue of Drug Discovery & Development for Ted Agres’ story on partnering.